COL1A1 as a potential new biomarker and therapeutic target for type 2 diabetes

Guopeng Lin,Xuzhi Wan,Dan Liu,Yuxi Wen,Chengfeng Yang,Chao Zhao
DOI: https://doi.org/10.1016/j.phrs.2021.105436
IF: 10.334
2021-03-01
Pharmacological Research
Abstract:<p>Type 2 diabetes (T2D) is a public health problem with a rising incidence worldwide. In this study, a potential new biomarker for T2D and mechanisms underlying the hypoglycemic effects of <em>Enteromorpha prolifera</em> oligosaccharide were investigated. Tandem mass tag labeling with LC–MS/MS was used to identify the differentially expressed proteins (DEPs) between the jejunum of diabetic rats and control rats. Correlations between glycometabolic parameters and DEPs were revealed by a network analysis. The expression levels of target genes in key metabolic pathways were further evaluated to identify candidate biomarkers. Among 6810 total proteins, approximately 88 % were quantified, of which 148 DEPs with a fold change of &lt;0.83 or &gt;1.2 and a corrected <em>p</em>-value of &lt;0.05 were identified. A KEGG enrichment analysis indicated that the hypoglycaemic effects of <em>E. prolifera</em> oligosaccharide involved the PI3K/AKT and extracellular matrix receptor interaction signaling pathways. More importantly, <em>Col1a1</em> was the most significant gene in the extracellular matrix receptor interaction pathway and was linked to hypoglycaemic activity for the first time. Thus, <em>Col1a1</em> is a novel potential therapeutic target for alleviating T2D.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?